Prognostic Value of Initial Magnetic Resonance Imaging Growth Rates for World Health Organization Grade II Glioma

Author: Pallud J. et al
Source: Ann Neurol 2006;60:380-383

Objective

To determine if MRI-based measurement of growth rate prior to treatment has prognostic value in grade II gliomas.

Methods

  • 143 consecutive patients diagnosed between 1992-2004
  • Older than 17 years of age
  • Absence of contrast enhancement
  • Astrocytoma, oligodendroglioma, or mixed glioma
  • At least 2 MRI studies pre-treatment, at least 3 months apart

Results

  • Patient characteristics
    • Median age 34
    • Symptoms at dx: 7 patients asymptomatic, 124 patients with seizures, 12 patients with headache, 7 patients with neurologic deficits
    • Median tumor volume 74.5 cm 3: 54 patients had histologic diagnosis via biopsy, 34 patients had partial resections, 40 had subtotal resections, and 15 had total resections
    • 92 oligodendrogliomas, 24 astrocytomas, 27 mixed histology
    • Median Ki-97 proliferation index 5% (72% of cases were assessable)
  • Radiology
    • Median of 3 tumor measurements prior to treatment
    • Median duration of repeat measurements was 21.7 months
    • Median Individual Radiological Growth Rate (IGR) 4.4 mm/year
    • Two Groups: 121 <8mm/year à low risk (LR) and 22 >8mm/year à high risk (HR)
    • No significant difference between the 2 groups regarding various demographics and treatment factors except that more biopsies done in LR group
  • Survival
    • Median clinical follow-up after radiologic diagnosis was 6.5 years
    • 18.1% of LR patients died during this time versus 45.5% in HR group; median time to death was 6.7 years in LR group and 4.9 years in HR group
    • Median survival was 5.16 years in HR group versus 15 years in LR group
    • Univariate Analysis: inverse correlation between IGR and survival (p<0.001); histology, tumor volume, age, neurologic deficits, and Ki-67 proliferation score not significant predictors of survival
    • Multivariate Analysis: IGR (p<0.0001) and tumor volume (p=0.034) were independent prognostic factors for survival

Discussion

  • IGR measurements prior to treatment in supratentorial grade II gliomas are predictive of prognosis
    • Previous studies have shown age >40, astrocytoma histology, tumor diameter >6 cm, neurologic defects, and lesions crossing midline have worse prognosis.
    • Lack of significance for several other prognostic factors may be due to small sample size.
  • Limitations of histologic diagnosis
    • Limited because it is "static"
    • Limited to part of the tumor, particularly in biopsies or partial resections
    • Conversely, tumor growth rate a macroscopic, dynamic parameter
    • In tumors growing >8 mm/year, worse prognosis despite absence of anaplastic transformation à seem to behave more like anaplastic gliomas with median survival of 5.16 years
  • Study may be limited as 2 MRIs may not accurately determine growth velocity

OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.


Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania